The biochemical, clinical, and genetic features of type III hyperlipoproteinemia
- PMID: 163608
- DOI: 10.7326/0003-4819-82-2-158
The biochemical, clinical, and genetic features of type III hyperlipoproteinemia
Abstract
The clinical and biochemical features of type III hyperlipoproteinemia are described in 49 patients from 23 to 70 years of age. An increase in very low-density lipoproteins (VLDL) of abnormal chemical composition was the basis for diagnosis. The untreated patients all had hypercholesterolemia and hyperglyceridemia, and, on the average, decreased concentrations of both low- and high-density lipoproteins. Seventy-four percent had xanthomas, and classic "xanthoma striata palmaris" was found in more than half. Twenty-seven percent had ischemic heart disease, detected earlier in men than in women. Twenty-seven percent had peripheral vascular disease (compared to 4% of subjects with type II hyperlipoproteinemia). Twenty-five of 35 subjects achieved normal lipid levels with dietary therapy alone. Analysis of 29 kindred showed hyperlipidemia in half of adult blood relatives; half of these had type III, the remainder usually had sample endogenous hyperglyceridemia (type IV). Only 2 of 55 children less than 20 years of age were affected, both with type IV.
Similar articles
-
Plasma lipoproteins and hyperlipoproteinemia.Acta Med Scand. 1973 May;193(5):369-72. doi: 10.1111/j.0954-6820.1973.tb10595.x. Acta Med Scand. 1973. PMID: 4352670 No abstract available.
-
Type 3 hyperlipoproteinaemia.Clin Endocrinol Metab. 1973 Mar;2(1):111-25. doi: 10.1016/s0300-595x(73)80029-5. Clin Endocrinol Metab. 1973. PMID: 4359114 No abstract available.
-
Familial hyperlipidemias. Diagnosis and treatment.Arch Dermatol. 1974 Jul;110(1):43-50. Arch Dermatol. 1974. PMID: 4371196 No abstract available.
-
Type IV hyperlipoproteinaemia.Clin Endocrinol Metab. 1973 Mar;2(1):41-71. doi: 10.1016/s0300-595x(73)80026-x. Clin Endocrinol Metab. 1973. PMID: 4359117 Review. No abstract available.
-
Diagnosis and management of hyperlipoproteinemia in infants and children.Am J Cardiol. 1973 May;31(5):547-56. doi: 10.1016/0002-9149(73)90322-6. Am J Cardiol. 1973. PMID: 4348998 Review. No abstract available.
Cited by
-
Hyperlipidemias and rheumatic manifestations.Clin Rheumatol. 1986 Jan;5(1):75-9. doi: 10.1007/BF02030972. Clin Rheumatol. 1986. PMID: 3485501
-
Unraveling hyperlipidemia type III (dysbetalipoproteinemia), slowly.Eur J Hum Genet. 2009 May;17(5):541-2. doi: 10.1038/ejhg.2008.222. Epub 2008 Nov 26. Eur J Hum Genet. 2009. PMID: 19034315 Free PMC article. No abstract available.
-
[Apolipoproteinopathies].Klin Wochenschr. 1983 Feb 15;61(4):169-82. doi: 10.1007/BF01488971. Klin Wochenschr. 1983. PMID: 6405080 German. No abstract available.
-
CREBH normalizes dyslipidemia and halts atherosclerosis in diabetes by decreasing circulating remnant lipoproteins.J Clin Invest. 2021 Nov 15;131(22):e153285. doi: 10.1172/JCI153285. J Clin Invest. 2021. PMID: 34491909 Free PMC article.
-
ApoE knockout and knockin mice: the history of their contribution to the understanding of atherogenesis.J Lipid Res. 2016 May;57(5):758-66. doi: 10.1194/jlr.R067249. Epub 2016 Mar 25. J Lipid Res. 2016. PMID: 27015743 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources